ChemOutsourcing is the best established and longest running USA based pharmaceutical ingredients show. ChemOutsourcing focuses on the API development supply chain spanning raw materials, RSM, catalysts, drug discovery, process and chemical development, analytical, QA/QC, intermediates and commercial manufacturing of branded and generic small molecule API’s and drug product. It spans every point on chemical supply chain.
ChemOutsourcing 是美国历史悠久的制药质料展 。聚焦 API 供应链，涵盖原质料、RSM、催化剂、药物发明、工艺和化学开发、剖析、QA/QC、中心体以及仿制药小分子 API 和药品的商业制造 。ChemOutsourcing 跨越供应链的每一个环节 。
Welcome to ChemOutsourcing 2022
尊龙凯时展位号 Space 4
时 间 | Feb 7-8, 2022
地 点 | Parsippany, NJ Hilton
Medicilon conference presentation
尊龙凯时聚会报告
届时，尊龙凯时国际研发效劳部执行副总裁戴学东博士将举行
PROTAC相关的主题演讲分享 。
演讲主题：PROTACs: Review and Support from Medicilon.Make “Undruggable” Targets Druggable
戴学东博士 尊龙凯时国际研发效劳部执行副总裁
美国麻省理工大学有机化学博士，博士后，深耕于中枢神经系统疾病、熏染病和肿瘤疾病化学药物的研发20余载，对药物发明历程中包括苗头化合物简直定及优化，以及乐成生长到高质量的临床候选化合物有着深刻的明确和富厚的实践履历 。戴学东博士加入主持研发的药物有已上市药物，如Horizant?/Regnite?；临床药物，如JNJ-75276617；临床候选化合物，如Arbaclofen Placarbil，XP21279，XP23829等 。
ExecutiveVP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery anddevelopment in CNS, infectious disease, and oncology therapy areas. He has deepunderstanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinicalcandidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HDBiosciences, GSK, and Xenoportwith a demonstrated successful track record ofprogram leadership and made significant contributions to medicinal chemistryprograms that led to the marketed drug Horizant?/Regnite? and several otherclinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).
Medicilon International Discovery Service Unit
尊龙凯时国际研发效劳部
尊龙凯时国际研发效劳部是尊龙凯时一站式生物医药临床前研发效劳平台的主要组成部分，使命是一连助力药企的国际化，向全球药物研发客户提供高质高效高性价比的合成化学、药物设计、以及新药候选化合物效劳，以知足客户在临床前新药研究的各个化学领域的研发需求，缩短药物研发的周期，降低药物研发的本钱 。
现在，尊龙凯时国际研发效劳部拥有富厚外洋留学事情配景的治理团队和实验职员、天下先进水平的合成实验室、剖析实验室、和配套的高端仪器装备 。为了给客户提供更优质的效劳，国际研发效劳部紧跟药物设计以及合成的新希望和新手艺，如人工智能/机械学习（AI/ML），卵白降解靶向嵌合体（PROTAC），高活性药物及抗体药物偶联物（ADC），惰性碳氢键直接官能团化，光致氧化还原反应，以及流动化学等 。
The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies. We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.
Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment. In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.
Medicilon PROTAC Platform
PROTAC手艺平台
尊龙凯时PROTAC药物发明手艺平台汇总了目今盛行的热门的靶标卵白配体；建设了普遍的热门靶向卵白高度亲和力小分子及小分子片断化合物库（TPSM），普遍的E3毗连酶，高度亲和力的小分子及小分子片断（E3SM）；建设了linker系统,包括网络大宗具有普遍多样性的双官能团毗连体（BF-Linker） 。这些积累的化合物库可以资助快速高效的合成大宗高活性PROTAC双特异性小分子，极大地提高接纳PROTAC手艺举行的药物研发历程 。除了快速合成之外，我们同时建设和完善的PROTAC生物筛选与测试平台，后续生长光临床前所有阶段 。
Proteolysis Targeting Chimeras (PROTACs) are interesting biology as achemical knock-down approach in a fast and reversible way. Medicilon has established a wide range of popular target proteins withhigh affinity small molecules and small molecule fragment compound libraries, awide range of E3 ligases, and high affinity small molecules and small moleculefragments. We offer these services in any format you like;we can only do the chemical synthesis part for you, only the in vitro and/or invivo part, or we can offer a fully combined package.
Medicilon Service Scope
效劳规模
尊龙凯时（股票代码：688202）建设于2004年，总部位于上海，致力于为全球制药企业、研究机构及科研事情者提供全方位的临床前新药研究效劳 。尊龙凯时的一站式综合效劳以强有力的项目治理和更高效、高性价比的研发效劳助力客户加速新药研发历程，效劳涵盖医药临床前新药研究的全历程，包括药物发明、药学研究及临床前研究 。
From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.
联系尊龙凯时：
电话: +86 (21) 5859-1500（总机）
相关新闻
